CLINICAL USES OF SEROMUCOID ESTIMATION

J. W. KEYSER, M.Sc., Ph.D.(Lond.), F.R.I.C.
Reader in Chemical Pathology, University of Wales, at The Welsh National School of Medicine; Honorary Consultant in Biochemistry, Cardiff United Hospitals.
From the Royal Infirmary, Cardiff

The seromucoid* fraction of the plasma proteins comprises a group of glycoproteins—i.e., protein-carbohydrate complexes—characterized by their solubility in certain protein precipitants (perchloric, sulphosalicylic and trichloroacetic acids) and by being not readily precipitated by heat. This fraction, which normally contains about 10% of the total protein-bound carbohydrate of the plasma and accounts for between 1% and 2% of the total plasma protein, may be estimated by precipitation from perchloric acid filtrates of serum by the addition of phosphotungstic acid, the protein or carbohydrate content of the precipitate being then determined (Winzler, Devor, Mehl and Smyth, 1948). From its solubility properties and method of estimation it would appear that the seromucoid fraction is essentially identical with the so-called 'polypeptides', 'peptones' or 'albumoses' extensively studied by earlier workers (Wolff, 1921; Hahn, 1921; Cristol, 1922; Goiffon and Spaey, 1934; Fiessinger, 1934; and others). Indeed, the presence in human serum of a heat-stable protein fraction soluble in acid protein-precipitating agents was recognized as long ago as 1892 (Freund), and this fraction was subsequently studied by Zanetti (1897), Bywaters (1906, 1909), Rimington (1940) and others. An excellent historical account is given by Sonnet (1956).

Variations—usually increases—in the plasma concentration of seromucoid are found in many conditions. The purpose of this brief review is to outline the principal diagnostic uses to which the estimation of seromucoid has been applied. No attempt is made to present an exhaustive account of the numerous clinical and other studies that have been made. Greenspan (1955) has suggested that the concentration of seromucoid is the resultant of an extremely labile interplay between two groups of non-specific factors: on the one hand tissue responses associated with inflammation, degeneration or trauma, which raise the seromucoid concentration, and on the other hand hepatic or endocrine insufficiency, which are associated with low concentrations. The seromucoid-enhancing factors usually predominate.

It must be emphasized that the seromucoid fraction, as prepared by treatment of serum with perchloric acid, contains a number of proteins, among which various workers have identified orosomucoid (α₁-acid glycoprotein), 3.5S α₁-glycoprotein and haptoglobin, as well as several others (Winzler, 1960; de Vaux St. Cyr, 1960). Since the individual components of the seromucoid fraction contain differing amounts of carbohydrate and may vary independently in their concentrations, it follows that estimations based on measurement of the protein content of the fraction will not necessarily agree with those based on measurement of its carbohydrate content. Variations in the carbohydrate/protein ratio have been stated to be of diagnostic value (see below).

It may be expected that specific determination of the individual glycoproteins, for example by immunochemical methods (cf. Gell, 1957; Easton, Hardwicke and Whitehead, 1962), will in the future provide more useful information than has been obtained by the methods used hitherto.

Diagnosis of Cancer

Some of the most striking increases in plasma seromucoid concentration are found in many types of cancer (Winzler and Smyth, 1948). In a series of 114 cases studied by Lockey, Anderson and Maclagan (1956), the highest values were recorded in patients with widely disseminated cancer; results were particularly striking in the lymphomata, while in malignant disease confined to bone very little elevation was found; and
other types of cancer occupied an intermediate position. However, comparable increases are found also in many other conditions (see Table); and this, together with the fact that normal seromucoid concentrations are found in some patients with cancer, especially when the disease is not far advanced, has led to the estimation's being regarded as of little practical value for detecting cancer (Winzler and Smyth, 1948; Henry, Berkman, Little and Winzler, 1951; Rhees, Ellerbrook and Lippincott, 1954). This view is disputed by Cameron, Campbell and Pledgerleith (1961a), who point out that most non-malignant conditions associated with a high concentration of plasma seromucoid are easily recognized and do not commonly enter into the diagnosis of cancer; consequently the test may often provide considerable diagnostic and prognostic information. In a series of 206 patients in whom malignancy was established, either histologically or at operation, or on the basis of clinical and radiological evidence, the majority (about 90%) had elevated seromucoid concentrations at the time of their first attendance at hospital; of those patients with normal concentrations, the majority had small tumours which had attracted attention at an early stage because of their superficial situation, and the diagnosis was apparent on clinical grounds. Normal concentrations are commonly found, for example, in patients with cancer of the breast (cf. Shetlar, Foster, Kelly, Shetlar, Bryan and Everett, 1949). There remained another group of patients in whom the test failed to detect cancer: these patients either had tumours of border-line malignancy, with little or no invasiveness, or else had small, early tumours of internal organs. In such cases, if other investigations prove unhelpful, repeated estimations of seromucoid at intervals may provide the earliest clue to the diagnosis (Cameron, Campbell and Pledgerleith, 1961a).

Occasionally even patients with advanced cancer may show no rise in seromucoid concentration. This was so with two patients in the terminal stages of gastric cancer, and Cameron and his co-authors suggest that the failure of the seromucoid concentration to increase in these two cases may be attributed to the presence of extensive hepatic metastases. This explanation should be accepted with reserve: in published series (Greenspan, Tepper, Terry and Schoenbach, 1952; Greenspan and Dreiling, 1953; Greenspan, 1954; Keyser, Payne and Stephens, 1962) the great majority of patients with hepatic metastases had elevated concentrations of seromucoid, only a few falling within the normal range. Indeed, some of the highest values found were in this group of patients. Nevertheless, it may well be that a certain minimal amount of normal liver tissue is required to produce elevated concentrations of seromucoid.

Seromucoid estimations can also be used to assess response to treatment, and in prognosis. Thus, Cameron and others found that successful treatment by radiotherapy, or with hormones or cytotoxic agents, is associated with a return of seromucoid concentrations to normal (cf. Keyser, 1954); and in patients treated surgically a sustained return of seromucoid concentrations to normal is an indication of adequate resection and a favourable prognosis (Cameron and others, 1961a).

In interpreting the significance of a raised concentration of seromucoid it is particularly important to bear in mind the influence of infection (see Table).

**Selection of Patients for Endocrine Ablation**

In the treatment of advanced cancer of the breast by endocrine ablation, remission is achieved in only a minority of patients, and when the employment of such procedures is considered the patient is usually in a feeble state. Burnett, McAllister and Shields (1963) therefore sought methods to help in the selection of patients likely to benefit from operation. In an investigation of 41 patients who underwent endocrine ablation for advanced cancer of the breast they found that very high concentrations of serum glycoproteins were associated with a poor prognosis. They suggest that patients with serum glycoprotein concentrations above certain limits are unlikely to benefit from endocrine ablation. Four serum glycoprotein 'indices' were measured, viz. total protein-bound carbohydrate, seromucoid-carbohydrate, seromucoid-tyrosine (a measure of the seromucoid-protein) and seromucoid estimated turbidimetrically. Of these, a knowledge of the seromucoid-
carbohydrate concentration was found to be the most useful.

Differential Diagnosis of Jaundice

A decreased concentration of seromucoid was reported by Greenspan and his co-workers in hepatocellular disease due to infective hepatitis, homologous serum hepatitis, toxic (chemically induced) hepatitis, and portal cirrhosis (Greenspan, Tepper, Terry and Schoenbach, 1952; Greenspan and Dreiling, 1953; Greenspan, 1954). Thus the incidence of a decreased seromucoid concentration was more than 80% in 83 patients with infective or homologous serum hepatitis and more than 70% in 94 patients with portal cirrhosis, whereas less than 3% of 146 patients with various forms of obstructive disease of the biliary tract had decreased concentrations (Greenspan, 1954). Most of the patients in the hepatitis-portal cirrhosis group that had normal or high seromucoid concentrations were suffering from coexistent septicaemia, pneumonia, peritonitis, tuberculosis, hepatoma or ulcerative colitis. All of these are conditions in which elevated seromucoid concentrations are found. As a result of their studies Greenspan and his collaborators proposed the estimation of the seromucoid concentration as a means of distinguishing between 'medical' and 'surgical' jaundice.

Greenspan and his collaborators also measured the ratio of 'polysaccharide' to protein in the seromucoid fraction. While patients with uncomplicated infective hepatitis, homologous serum hepatitis or portal cirrhosis had an increased 'polysaccharide'/protein ratio, patients with neoplastic infiltration of the liver, associated with hepatomegaly, had essentially normal ratios; and measurement of these ratios, as well as of the actual seromucoid (protein) concentration, was thought to be clinically useful in the differentiation of neoplastic from primary parenchymatous disease of the liver (Greenspan, Lehman, Graff and Schoenbach, 1951; Greenspan, Tepper and Schoenbach, 1951; Greenspan and others, 1952).

Mandel, Gorsuch and Cooper (1955) found a somewhat lower incidence of subnormal seromucoid concentrations both in viral hepatitis and in alcoholic cirrhosis (39% and 15%, respectively; increasing to 50% and 43% when patients with complicating extrahepatic disease processes were excluded). No subnormal values were found in biliary obstruction. Mandel and his collaborators concluded that a definite diagnostic value could be attached only to the finding of a subnormal concentration of seromucoid; in association with jaundice or hepatomegaly, or both, and in the absence of a nephrotic syndrome (Kelley, Good, Glick and Ochs, 1950), of excessive hyperglobulinæmia and, perhaps, of certain endocrinopathies (Greenspan, 1954), this was almost pathognomonic of hepatocellular disease. On the other hand the finding of a normal or elevated concentration was of very limited value.

Varay and Masson (1960) confirmed the tendency for the seromucoid concentration to be below average in hepatitis, though inspection of their results suggests that in fact only two out of 24 patients with this disease had concentrations definitely below the normal range. Raised concentrations were found in patients with obstructive jaundice, whether the obstruction was extra- or intra-hepatic. Results in cirrhosis were variable; it would appear that infections were responsible for high values in many cases. Very high values were found in five patients with cancer of the liver.

Cameron, Campbell and Plenderleith (1961b) reported essentially normal values in patients with hepatic cirrhosis, and considerable overlapping of the normal range in patients with infective hepatitis. Keyser and others (1962) confirmed the existence of raised seromucoid concentrations in most patients with obstructive jaundice, and especially in most patients with obstruction due to carcinoma or with secondary deposits of carcinoma in the liver; in agreement with Mandel and his colleagues, only a minority of patients with hepatocellular disease were found to have a lowered seromucoid concentration.

Shields, McAllister and Burnett (1963), who made a similar study, concluded that estimation of the seromucoid concentration was of great value in distinguishing hepatic from post-hepatic jaundice. Indeed, they found the estimation of seromucoid-'tyrosine' more useful in differential diagnosis than the conventional tests, especially in the absence of current extra-hepatic disease.

The estimation of seromucoid would seem, then, to have a place in the differential diagnosis of hepatobiliary disease, provided that the results are interpreted cautiously, with due regard to the many factors that may influence the concentration of this fraction. Because of this limitation it is not to be expected that the estimation will help decisively in more than a minority of cases.

According to Greenspan, 'intraglobulin fractional analysis' by a battery of four determinations—seromucoid, 'acid-precipitable globulin turbidity' (a measure of α₂ plus β-globulins), zinc sulphate turbidity and total protein-bound hexose—compares favourably with the cephalin flocculation test, estimation of alkaline phosphatase and other established aids in the differential diagnosis of
jaundice (Greenspan, 1956; Greenspan and Dreiling, 1957).

Cameron, Campbell and Pledgerleith (1962) used the seromucoid estimation to help in the investigation of upper gastrointestinal haemorrhage. They concluded that oesophageal varices, peptic ulcer and carcinoma of the stomach tended to be associated with low, normal and high seromucoid concentrations respectively.

Assessment of Activity in Various Diseases

A number of investigators have correlated seromucoid concentration with the degree of clinical activity in various diseases. For example, Turner, Schaffner, Eshbaugh and de la Huerga (1953) found that a high seromucoid concentration in the presence of known pulmonary tuberculosis strongly suggests that the disease is far advanced, and extremely high values were thought to indicate a very poor prognosis. Shetlar and Payne (1958) found a significant correlation between the seromucoid (and also total glycoprotein) concentration and the degree of inflammatory activity in patients with rheumatoid arthritis. Patients with 'psychogenic rheumatism' had normal concentrations (Shetlar, Payne, Bullock, Patrick, Hellbaum and Ishmael, 1953). In rheumatic fever also the seromucoid concentration is considerably increased when the disease is active, but only slightly increased when it is not (Shetlar, 1958). In patients with myopathies, motor neurone disease and allied conditions those patients who appeared clinically to be actively wasting showed the highest seromucoid concentrations (Keyser, Jenkins, Lloyd, Pallis and Sanders, 1957). (This last investigation was undertaken not so much with the object of seeking aids to diagnosis as to obtain evidence for an association between increased glycoprotein concentrations and tissue breakdown (cf. Seibert, Seibert, Atno and Campbell, 1947).

More recently, a raised seromucoid concentration has been found to be associated with other evidence of clinical activity of the intestinal lesion in patients with regional ileitis or ulcerative colitis (Cooke, Fowler, Cox, Gaddie and Meynell, 1958). The use of the seromucoid estimation in gastroenterology to detect and obtain an estimate of the degree of activity in new patients, and also to check response to therapy, and in long-term follow-up, is summarized by Fowler and Cooke (1961).

Other applications of seromucoid estimation, such as the investigation of renal disease and the diagnosis of myeloma, are described by Varay and Masson (1960). Sonnet (1956) discusses in detail the findings in a number of diseases, particularly the paraproteinæmas.

'Mucoproteins' of Ascitic, Pleural and Cerebrospinal Fluids

A number of investigators have examined other body fluids besides blood for their content of 'mucoprotein' (i.e., perchloric acid-soluble, phosphotungstic acid-precipitable proteins) in various diseases. Taipale and Hokkanen (1956) studied the mucoprotein concentration of ascitic and pleural fluids. The concentration in ascitic fluid was lowest in patients with liver cirrhosis; the highest values were found in fluids from patients with malignant tumours; patients with congestive heart failure occupied an intermediate position, and in this group the lowest values were found in patients with cardiac cirrhosis. Taipale and Hokkanen concluded that determination of the mucoprotein of the ascitic fluid is of diagnostic significance, the corresponding serum concentrations in these three groups showing noticeably smaller differences. The findings of Spak (1960) and of Lopez and Kozma (1961) also suggest that the estimation of this fraction in ascitic fluid may be useful in diagnosis. Estimation of the mucoprotein in pleural fluid, however, did not appear to have any diagnostic value (Taipale and Hokkanen).

Biserte, Havez, Guerrin, Laturaze and Hayem (1961) investigated the electrophoretic and immunoelectrophoretic properties of ascitic fluids of different types (neoplastic, cirrhotic and cardiac). Orosomucoid, which is the major constituent of perchloric acid filtrates, was present in all the fluids examined, but was found in the greatest concentration in neoplastic ascitic fluids. Haptoglobin was found always in neoplastic fluids but in only a few fluids of cirrhotic origin. One glycoprotein, designated seromucoid $\beta_1$ ($\beta_1$-globulin), was found to be characteristic of exudates of cancerous origin; like haptoglobin, it was often absent from fluids of cirrhotic origin. All these glycoproteins are soluble in perchloric acid (0.6 – 0.8M).

Roboz, Apostol, Luft and Hess (1957) reported high concentrations of mucoprotein in the cerebrospinal fluid of patients with tumours of the central nervous system; and according to Zlotnick, Weisenberg and Chowers (1959) a high concentration of mucoprotein in the cerebrospinal fluid suggests the presence of a tumour of the central nervous system in cases where an acute infection or an abscess can be ruled out. However, Silverstein and Greenspan (1959) could not detect mucoprotein in the cerebrospinal fluid of about two-thirds of the patients they investigated;
although there did appear to be a higher incidence of c.s.f. mucoprotein in patients with neoplasms of the central nervous system, or with proven occlusive cerebral vascular disease, the finding of mucoprotein in the fluid of patients without neurological disease (in the same frequency and amounts as in the whole group of patients with neurological disease) appeared to limit the value of the investigation. BAKER (1957) has analysed the perichloric acid-soluble, phosphotungstic acid-precipitable fraction of cerebrospinal fluid and has found that it differs from seromucoid of blood in respect of both carbohydrate content and electrophoretic mobility.

**Summary**

The clinical applications of seromucoid estimation, especially in the diagnosis of cancer, the selection of patients for endocrine ablation, the differential diagnosis of jaundice, and the assessment of activity in various diseases, are briefly described.

I am grateful to Professor J. Gough, M.D., and Mr. R. Shields, M.B., Ch.B., for their helpful criticisms and suggestions.

**References**


---, --- (1957): Intraglobulin Fractional Analysis as an Aid in the Differentiation of Medical from Surgical Jaundice, Gastroenterology, 32, 500.

---, --- (1951): A Comparative Study of the Serum Glycoproteins in Patients with Parenchymatous Hepatic Disease or Metastatic Neoplasia, Cancer, 4, 972.


---, ---, --- (1952): The Serum Mucoproteins as an Aid in the Differentiation of Neoplastic from Primary Parenchymatous Liver Disease, J. Lab. clin. Med., 39, 44.


KEYSER: Clinical Uses of Seromucoid Estimation

189

April 1964


Clinical Uses of Seromucoid Estimation

J. W. Keyser

doi: 10.1136/pgmj.40.462.184

Updated information and services can be found at:
http://pmj.bmj.com/content/40/462/184.citation

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/